van der Pluijm RW, Tripura R, Hoglund RM, et al. - Major threats to malaria control and elimination is artemisinin and partner-drug resistance in Plasmodium falciparum. Researchers here examined if triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, are effective treatment and could delay emergence of antimalarial drug resistance. Recruitment of patients with uncomplicated P falciparum malaria was done at 18 hospitals and health clinics in eight countries for this multicentre, open-label, randomized trial. Between Aug 7, 2015, and Feb 8, 2018, they randomly assigned 1,100 patients (1:1) to receive one of two treatments using block randomization, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether–lumefantrine or artemether–lumefantrine plus amodiaquine. Outcomes support the efficacy as well as good tolerability, and safety of dihydroartemisinin–piperaquine plus mefloquine and artemether–lumefantrine plus amodiaquine TACTs for treating uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance.